Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29054813 | 0.86 | KCNA3 (0.64) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL8871233 | 0.86 | ALOX15 (0.60) | MEN1KMT2AALDH1A1CA12CA1 | |
| SCHEMBL29054826 | 0.85 | KCNA3 (0.66) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL29054926 | 0.84 | KCNA3 (0.64) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL29054840 | 0.84 | KCNA3 (0.64) | MEN1KMT2ACA12CA1CA9 | |
| SCHEMBL14473803 | 0.84 | KCNA3 (0.63) | MEN1KMT2AKDM4EALDH1A1CA12 | |
| SCHEMBL8397889 | 0.81 | KCNA3 (0.59) | MEN1KMT2AKDM4EALDH1A1CA12 | |
| SCHEMBL15842782 | 0.79 | CYP2A6 (0.67) | KDM4EALDH1A1CA12CA1CA9 | |
| SCHEMBL3921262 | 0.77 | LMNA (0.62) | KDM4EALDH1A1CA12CA1CA9 | |
| SCHEMBL24523066 | 0.77 | ALDH1A1 (0.59) | MEN1KMT2AKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| WO-2013003168-A1 | NOVEL INSECT-REPELLENT COUMARIN DERIVATIVES, SYNTHESES, AND METHODS OF USE | MERIAL LIMITED (US) | 2013-01-03 | — | — | WO | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1951260-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | Bezwada Biomedical LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | COMT, AOX1, UGT1A6 | MEN1 4822/4885KMT2A 3325/4885KDM4E 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.